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Abstract For the purpose of nationwide surveillance of
the antimicrobial susceptibility of bacterial respiratory
pathogens collected from patients in Japan, the Japanese
Society of Chemotherapy conducted a third year of
nationwide surveillance during the period from January to
April 2008. A total of 1,097 strains were collected from
clinical specimens obtained from well-diagnosed adult
patients with respiratory tract infections. Susceptibility
testing was evaluable with 987 strains (189 Staphylococcus
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aureus, 211 Streptococcus pneumoniae, 6 Streptococcus
pyogenes, 187 Haemophilus inﬂuenzae, 106 Moraxella
catarrhalis, 126 Klebsiella pneumoniae, and 162 Pseudo-
monas aeruginosa). A total of 44 antibacterial agents,
including 26 b-lactams (four penicillins, three penicillins in
combination with b-lactamase inhibitors, four oral cep-
hems, eight parenteral cephems, one monobactam, ﬁve
carbapenems, and one penem), three aminoglycosides, four
macrolides (including a ketolide), one lincosamide, one
tetracycline, two glycopeptides, six ﬂuoroquinolones, and
one oxazolidinone were used for the study. Analysis was
conducted at the central reference laboratory according to
the method recommended by the Clinical and Laboratory
Standard Institute (CLSI). The incidence of methicillin-
resistant S. aureus (MRSA) was as high as 59.8%, and
those of penicillin-intermediate and penicillin-resistant
S. pneumoniae (PISP and PRSP) were 35.5 and 11.8%,
respectively. Among H. inﬂuenzae, 13.9% of them
were found to be b-lactamase-non-producing ampicillin
(ABPC)-intermediately resistant (BLNAI), 26.7% to be
b-lactamase-non-producing ABPC-resistant (BLNAR), and
5.3% to be b-lactamase-producing ABPC-resistant (BLPAR)
strains. A high frequency (76.5%) of b-lactamase-producing
strains was suspected inMoraxella catarrhalis isolates. Four
(3.2%) extended-spectrum b-lactamase-producing K. pneu-
moniaewere found among 126 strains. Four isolates (2.5%) of
P. aeruginosa were found to be metallo b-lactamase-pro-
ducing strains, including three (1.9%) suspected multidrug-
resistant strains showing resistance to imipenem, amikacin,
and ciproﬂoxacin. Continual national surveillance of the
antimicrobial susceptibility of respiratory pathogens is crucial
in order to monitor changing patterns of susceptibility and to
be able to update treatment recommendations on a regular
basis.
Keywords Surveillance  Susceptibility  Resistance 
Respiratory tract infection
Introduction
In order to investigate comprehensively the antimicrobial
susceptibility and resistance of bacterial respiratory
pathogens, the Japanese Society of Chemotherapy (JSC)
established a nationwide surveillance network in 2006. The
ﬁrst and second surveys were conducted during the periods
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from January to August in 2006 and 2007, and we reported the
trend of antimicrobial susceptibilities of bacterial species iso-
lated from patients with respiratory tract infections (RTIs)
(Niki et al. [14]). Here we report the study of the third year of
nationwide surveillance conducted by the JSC during the per-
iod from January to April 2008. The results obtained from this
survey will be used as a set of controls for those surveys to be
conducted in future by the JSC and by other organizations as
well.
Materials and methods
Strains and quality control
The causative bacteria from patients with RTIs were isolated
from sputum, specimens collected by trans-tracheal aspiration,
or bronchoscopy. Microbiological laboratory tests for respira-
tory pathogenswere conducted by standardmethods, including
Gram staining and quantitative culture of various respiratory
samples, at 46 medical institutions, as listed in Table 1. The
isolated bacteria were identiﬁed at the species level in each
institution’s laboratory. The isolates were suspended inMicro-
bank tubes (Asuka Junyaku, Tokyo, Japan) and transferred to
the central laboratory, the Research Center for Anti-infective
Drugs of the Kitasato Institute (hereafter, the Center). Elec-
tronic uniform data sheets of each patient from whom these
strains isolatedwere also completed at each institution and sent
to the Center so that the microbiological data obtained were
able to be stratiﬁed according to the settings and proﬁles of the
patients and according to the diagnoses.
A total of 1,097 strainswere received at theCenter and kept
at -80C until the antimicrobial susceptibility testing was
conducted. Re-identiﬁcation and culture of them gave 987
evaluable strains, consisting of 189 Staphylococcus aureus,
211 Streptococcus pneumoniae, 6 Streptococcus pyogenes,
187Haemophilus inﬂuenzae, 106Moraxella catarrhalis, 126
Klebsiella pneumoniae, and 162 Pseudomonas aeruginosa.
Accuracy of determination of the minimum inhibitory
concentration (MIC) of antibacterial agents was controlled
according to the recommendations of the Clinical and Labo-
ratory Standards Institute (CLSI), using the following control
strains, respectively: S. aureus ATCC29213 and Escherichia
coli ATCC35218 for clinical isolates of S. aureus and M.
catarrhalis; S. pneumoniae ATCC49619 for those of S.
pneumoniae and S. pyogenes; H. inﬂuenzae ATCC49247 for
H. inﬂuenzae; E. coli ATCC25922 for K. pneumoniae and P.
aeruginosa; and P. aeruginosa ATCC27853 for P. aerugin-
osa. E. coli ATCC35218 was used as a control strain for the
MIC determination of b-lactam antibiotics combined with b-
lactamase inhibitors.
Table 1 List of participating institutions contributing to our
surveillance
Aichi Medical University Hospital, Nagakute, Aichi
Faculty of Medicine, University of the Ryukyus, Nishihara,
Okinawa
Fukushima Prefectural Aizu General Hospital, Aizuwakamatsu,
Fukushima
Hiroshima Prefectural Hospital, Hiroshima, Hiroshima
Hospital of the Kinki University School of Medicine,
Osakasayama, Osaka
Hyogo College of Medicine, Nisinomiya, Hyogo
Iwate Prefectural Central Hospital, Morioka, Iwate
Japanese Red Cross Sendai Hospital, Sendai, Miyagi
Kasugai Municipal Hospital, Kasugai, Aichi
Kawasaki Medical School Hospital, Kurashiki, Okayama
Kyorin University Hospital, Mitaka, Tokyo
Matsue Red Cross Hospital, Matsue, Shimane
Nagasaki University School of Medicine, Nagasaki, Nagasaki
Nara Hospital, Kinki University School of Medicine, Ikoma, Nara
Nara Medical University Center for Infectious Diseases, Kashihara,
Nara
National Hospital Organization Tokyo Medical Center, Meguro,
Tokyo
Niigata City General Hospital, Niigata, Niigata
Oita University Faculty of Medicine, Yufu, Oita
Okayama University Hospital, Okayama, Okayama
Osaka City General Hospital, Miyakojima, Osaka
SagaMedical School Faculty ofMedicine, SagaUniversity, Saga, Saga
Saga University Hospital, Saga, Saga
Showa University, School of Medicine, Shinagawa, Tokyo
St. Luke’s International Hospital, Chuo, Tokyo
St. Mary’s Hospital, Kurume, Fukuoka
Saka General Hospital, Shiogama, Miyagi
Sanyudo Hospital, Yonezawa, Yamagata
Shimonoseki City Hospital, Shimonoseki, Yamaguchi
Shinrakuen Hospital, Niigata, Niigata
Teikyo University Hospital, Itabashi, Tokyo
Tokyo Metropolitan Health and Medical Corporation Toshima
Hospital, Itabashi, Tokyo
Toyama Prefectural Central Hospital, Toyama, Toyama
University of Occupational And Environmental Health Hospital,
Kitakyusyu, Fukuoka
Yamagata Saisei Hospital, Yamagata, Yamagata
Y. Aoki
Saga Medical School Faculty of Medicine, Saga University,
Saga, Japan
Z. Nagasawa
Saga University Hospital, Saga, Japan
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Susceptibility testing and MIC determination
Susceptibility testing was performed according to CLSI
(formerly NCCLS) standards M7-A7 [1] for the microbroth
dilution method. In brief, cation-adjusted Mueller-Hinton
broth (25 mg/L Ca?? and 12.5 mg/L Mg??; CA-MH
broth) was used to measure the MICs against S. aureus, M.
catarrhalis, K. pneumoniae, and P. aeruginosa. For the
determination of the MIC of oxacillin, NaCl was added at
2% to CA-MH broth. For measuring the MICs against S.
pneumoniae, S. pyogenes, and H. inﬂuenzae, 15 lg/mL
nicotinamide, 5 mg/mL yeast extract, and horse blood at
5% were added to CA-MH broth.
A 0.005 mL portion of test organism solution, grown to
turbidity of MacFarland Number 0.5 and diluted tenfold
with saline, was inoculated to CA-MH broth to make a ﬁnal
volume of 0.1 ± 0.02 mL. This was poured into a well
on a microplate (Eiken Kagaku, Tokyo, Japan) where a
serially diluted freeze-dried test agent was placed, and the
MIC was determined with the MIC2000 system (Eiken
Kagaku).
Antibacterial agents
The susceptibilities of the bacterial strains were tested for the
following 44 antimicrobial agents: four penicillins – ben-
zylpenicillin (PCG; Meiji Seika Kaisha), oxacillin (MPIPC;
Meiji), ampicillin (ABPC; Meiji), and piperacillin (PIPC;
Toyama Chemical); three penicillins in combination with
b-lactamase inhibitors – clavulanic acid-amoxicillin (CVA/
AMPC; Glaxo SmithKline.), sulbactam-ABPC (SBT/
ABPC; Pﬁzer Japan), and tazobactam-PIPC (TAZ/PIPC;
Toyama); four oral cephems – cefaclor (CCL; Shionogi),
cefdinir (CFDN; Astellas Pharma), cefcapene (CFPN;
Shionogi), and cefditoren (CDTR; Meiji); eight parenteral
cephems – cefazolin (CEZ;Astellas), cefoxitin (CFX;Banyu
Pharmaceutical), cefmetazole (CMZ; Daiichi-Sankyo),
cefotiam (CTM; Takeda Pharmaceutical), ceftazidime
(CAZ; Glaxo SmithKline), ceftriaxone (CTRX; Chugai
Pharmaceutical), cefepime (CFPM; Meiji), and cefozopran
(CZOP; Takeda); a monobactam – aztreonam (AZT; Eisai);
ﬁve carbapenems – imipenem (IPM; Banyu), panipenem
(PAPM; Daiichi-Sankyo), meropenem (MEPM; Dainippon
Sumitomo,), biapenem (BIPM;Meiji), and doripenem
(DRPM; Shionogi); one penem – faropenem(FRPM; Astel-
las); three aminoglycosides – gentamicin (GM; Shionogi),
amikacin (AMK;Banyu), and arbekacin (ABK; Meiji); four
macrolides – erythromycin (EM; Dainippon Sumitomo),
clarithromycin (CAM; Toyama), azithromycin (AZM;
Pﬁzer), and telithromycin (TEL; Sanoﬁ-Aventis); a linco-
samide – clindamycin (CLDM; Dainippon Sumitomo.); a
tetracycline – minocycline (MINO; Wyeth /Takeda); two
glycopeptides – vancomycin (VCM; Shionogi) and
teicoplanin (TEIC; Astellas); six ﬂuoroquinolones – cipro-
ﬂoxacin (CPFX; BayerYakuhin), levoﬂoxacin (LVFX;
Daiichi-Sankyo), tosuﬂoxacin (TFLX; Toyama), gatiﬂoxa-
cin (GFLX; Kyorin Pharmaceutical), moxiﬂoxacin(MFLX;
Shionogi), and pazuﬂoxacin (PZFX; Toyama); and an oxa-
zolidinone – linezolide (LZD; Pﬁzer). These antimicrobial
agents were serially diluted and placed in a freeze-dried state
in the appropriate wells of microplates. The stability of the
antimicrobial agent-containing microplates was guaranteed
by the manufacturer (Eiken Kagaku) for 9 months.
Detection of b-lactamases
To detect b-lactamases in H. inﬂuenzae, tests with Nitr-
oceﬁn disks (Kanto Chemical, Tokyo, Japan) were con-
ducted according to the reference manual supplied by the
manufacturer.
A recently established rapid detection method, the Cica-
Beta Test 1 (Kanto Chemical, Tokyo, Japan), designed to
detect extended-spectrum b-lactamase (ESBL) and metallo
b-lactamase (MBL) directly in colonies of Gram-negative
rods [2, 3], was employed to identify K. pneumoniae and
P. aeruginosa strains which produce such b-lactamases.
Results
Staphylococcus aureus
The in vitro antimicrobial susceptibilities, as MIC50/MIC90
values, and the range of MICs for S. aureus isolates are
shown in Table 2. Among the total 189 strains of S. aureus,
113 strains (59.8%) were found to be methicillin-resistant
S. aureus (MRSA; MIC of MPIPC C 4 lg/mL).
Susceptibility of methicillin-susceptible S. aureus (MSSA)
The MIC90s of penicillins against 76 MSSA strains were
16–64 lg/mL; however, the MIC90s of penicillins in
combinations with b-lactamase inhibitors (CVA/AMPC,
SBT/ABPC, and TAZ/PIPC) decreased to 2.0–4.0 lg/mL.
The MIC90s of CCL, CAZ, CTRX, CFPM, and CMZ
ranged from 1.0 to 8.0 lg/mL, and those of the other seven
cephems ranged from 0.25 to 1.0 lg/mL. Carbapenems
showed the strongest activity, with MIC90s of B0.125 lg/
mL. As for the aminoglycosides, GM, AMK, and ABK
showed MIC90s of 8.0, 8.0, and 0.5 lg/mL, respectively.
Among the macrolide-lincosamide antibiotics, TEL and
CLDM showed relatively strong activity, with MIC90s of
0.25 and 0.5 lg/mL, respectively, but the rest of the
macrolides showed weak activity, with MIC90s of
C128 lg/mL. Relatively strong activities of MINO, VCM,
TEIC, and LZD were shown, with MIC90s of 0.125–2.0 lg/
J Infect Chemother (2011) 17:510–523 513
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Table 2 Antibacterial susceptibility of Staphylococcus aureus
Antibacterial
agent
All strains (n = 189) MSSA (MPIPC B 2 lg/mL) (n = 76) MRSA (MPIPC C 4 lg/mL) (n = 113)
MIC (lg/mL) MIC (lg/mL) MIC (lg/mL)
50% 90% Range 50% 90% Range 50% 90% Range
Benzylpenicillin 16 32 B0.06 to 128 0.5 16 B0.06 to 128 16 64 8 to 64
Ampicillin 16 64 0.125 to 128 0.5 16 0.125 to 128 32 64 8 to 128
Ampicillin/Sulbactam 16 32 0.125 to 64 0.25 4 0.125 to 8 16 32 4 to 64
Amoxicillin/Clavulanic acid 16 32 0.125 to 64 0.25 2 0.125 to 2 32 64 8 to 64
Piperacillin 64 C256 0.5 to C256 2 64 0.5 to C256 128 C256 16 to C256
Piperacillin/Tazobactam 64 128 0.25 to C256 0.5 2 0.25 to 4 128 C256 8 to C256
Cefaclor 128 C256 0.5 to C256 1 4 0.5 to 8 128 C256 16 to C256
Cefdinir 64 C128 B0.06 to C128 0.25 0.25 B0.06 to 0.5 C128 C128 0.5 to C128
Cefcapene C256 C256 0.25 to C256 1 1 0.25 to 2 C256 C256 16 to C256
Cefditoren 64 C128 0.25 to C128 0.5 1 0.25 to 2 64 C128 8 to C128
Cefazolin 128 C256 0.25 to C256 0.5 0.5 0.25 to 2 C256 C256 4 to C256
Cefotiam 64 C256 0.5 to C256 0.5 1 0.5 to 2 C256 C256 4 to C256
Ceftazidime C128 C128 4 to C128 8 8 4 to 8 C128 C128 32 to C128
Ceftriaxone C256 C256 1 to C256 4 4 1 to 8 C256 C256 32 to C256
Cefepime 128 C256 0.5 to C256 2 4 0.5 to 4 128 C256 8 to C256
Cefozopran 16 64 0.25 to 128 0.5 1 0.25 to 1 32 64 1 to 128
Cefmetazole 32 64 0.5 to C256 1 1 0.5 to 2 32 64 8 to C256
Imipenem 8 64 B0.06 to C128 B0.06 0.125 B0.06 to 0.125 32 64 0.25 to C128
Panipenem 8 32 B0.06 to 128 B0.06 0.125 B0.06 to 0.25 16 64 0.25 to 128
Meropenem 8 32 B0.06 to 128 0.125 0.125 B0.06 to 0.25 16 64 1 to 128
Biapenem 8 64 B0.06 to 128 B0.06 0.125 B0.06 to 0.125 32 64 1 to 128
Doripenem 8 16 B0.06 to 64 B0.06 B0.06 B0.06 to 0.125 8 32 0.5 to 64
Faropenem 32 C256 B0.06 to C256 0.125 0.125 B0.06 to 0.25 C256 C256 0.25 to C256
Gentamicin 0.5 64 0.125 to C256 0.25 8 0.25 to C256 32 128 0.125 to C256
Amikacin 8 16 1 to 128 2 8 1 to 16 8 32 2 to 128
Arbekacin 0.5 1 0.25 to 8 0.5 0.5 0.25 to 2 0.5 2 0.25 to 8
Ciproﬂoxacin 16 C256 0.125 to C256 0.5 8 0.125 to C256 128 C256 0.25 to C256
Levoﬂoxacin 8 C256 0.125 to C256 0.25 8 0.125 to C256 32 C256 0.25 to C256
Tosuﬂoxacin C32 C32 B0.06 to C32 B0.06 4 B0.06 to C32 C32 C32 B0.06 to C32
Gatiﬂoxacin 4 64 B0.06 to C256 0.125 2 B0.06 to 64 8 64 B0.06 to C256
Pazuﬂoxacin 8 C256 0.125 to C256 0.25 8 0.125 to C256 16 C256 0.125 to C256
Moxiﬂoxacin 2 64 B0.06 to 64 B0.06 2 B0.06 to 64 8 64 B0.06 to 64
Minocycline 0.25 16 B0.06 to 16 0.125 0.125 B0.06 to 16 8 16 B0.06 to 16
Erythromycin C256 C256 0.125 to C256 0.25 C256 0.125 to C256 C256 C256 0.25 to C256
Clarithromycin C128 C128 0.125 to C128 0.25 C128 0.125 to C128 C128 C128 0.25 to C128
Azithromycin C128 C128 0.25 to C128 0.5 C128 0.25 to C128 C128 C128 0.5 to C128
Telithromycin C64 C64 B0.06 to C64 B0.06 0.25 B0.06 to C64 C64 C64 B0.06 to C64
Clindamycin C256 C256 B0.06 to C256 0.125 0.5 B0.06 to C256 C256 C256 0.125 to C256
Vancomycin 1 2 0.5 to 2 1 1 0.5 to 2 1 2 0.5 to 2
Teicoplanin 0.5 2 0.125 to 8 0.5 1 0.125 to 2 0.5 2 0.25 to 8
Linezolide 2 2 0.5 to 4 2 2 1 to 4 1 2 0.5 to 2
Oxacillin 128 C256 0.125 to C256 0.25 0.5 0.125 to 1 C256 C256 32 to C256
Cefoxitin 64 C128 1 to C128 4 4 1 to 4 C128 C128 4 to C128
Susceptibilities of the 189 strains of S. aureus to 43 antimicrobial agents were measured. The strains consisted of 113 strains (59.8%) of methicillin-
resistant S. aureus and 76 strains (40.2%) of methicillin-susceptible S. aureus
MRSA methicillin-resistant S. aureus, MSSA methicillin-susceptible S. aureus, MIC minimum inhibitory concentration, MPIPC Oxacillin
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mL. The MIC90s of the six ﬂuoroquinolones were within
the range of 2.0–8.0 lg/mL.
Susceptibility of MRSA
Only four agents—ABK, VCM, TEIC, and LZD—showed
strong activity against MRSA, with an MIC90 of 2.0 lg/
mL. MINO showed weak activity, with an MIC90 of 16 lg/
mL. Other agents showed almost no activity, with MIC90s
of C32 lg/mL.
Streptococcus pneumoniae
The susceptibilities of the 211 strains of S. pneumoniae to
PCG revealed that 111 strains (52.6%), 75 strains (35.5%),
and 25 strains (11.8%) were identiﬁed as penicillin-sus-
ceptible (PSSP), penicillin-intermediate (PISP), and peni-
cillin-resistant strains (PRSP), respectively, with the
breakpoint for PCG deﬁned by the CLSI standards [1].
However, with the new Food and Drug Administration
(FDA) criteria for breakpoint MICs for S. pneumoniae
strains isolated from patients with pneumonia, 210 strains
(99.5%), and 1 strain (0.5%), were classiﬁed as susceptible
(MIC: B2 lg/mL), and intermediate (MIC: 4 lg/mL),
respectively. No isolate among the stains we tested was
found to be resistant (MIC: C8 lg/mL).
Among the b-lactams, CCL and CAZ showed high
MIC90s (128 and 32 lg/mL, respectively) while many of
the other b-lactams, except for the carbapenems, showed
potent activities, with MIC90s of 2.0–4.0 lg/mL. All ﬁve
carbapenems showed strong activities (MIC90: B0.5 lg/
mL) against all S. pneumoniae strains, regardless of their
different susceptibilities to PCG. Fluoroquinolones also
showed potent activities against most of the strains, with
MIC90s of 0.25–4 lg/mL, whereas 5 strains (2.4%) were
found to be resistant to LVFX. The glycopeptides (VCM
and TEIC), and TEL showed strong activities (MIC90:
B0.5 lg/mL). Aminoglycosides were substantially less
active, with MIC90s of 8.0–64.0 lg/mL. High frequencies
of resistance to the macrolide antibiotics, EM, CAM, and
AZM, were shown, with MIC90s of C128 lg/mL
(Table 3).
Haemophilus inﬂuenzae
The susceptibilities of the 187 H. inﬂuenzae strains are
summarized in Table 4. According to the CLSI breakpoint
for ABPC [1], 101 strains (54.0%) were found to be ABPC-
susceptible, 26 (13.9%) to be ABPC-intermediate, and 60
(32.1%) to be ABPC-resistant. With the use of the Nitr-
ocephin disks, all ABPC-intermediate and 50 (26.7%)
ABPC-resistant strains were found to be b-lactamase-non-
producing, and they were deﬁned as BLNAI and BLNAR,
respectively. The other 10 (5.3%) ABPC-resistant strains
were found to be b-lactamase-producing strains, designated
as BLPAR. The MIC50 and MIC90 values of PCG and
ABPC for BLPAR isolates were at least ﬁvefold higher
than those for BLNAR isolates. However, there were no
differences in the MIC50 and MIC90 values of SBT/ABPC
and CVA/AMPC among BLNAR isolates and BLPAR
isolates. Regardless of susceptibility to ABPC, all of the
H. inﬂuenzae strains were extremely susceptible to all six
ﬂuoroquinolones (MIC50s: B0.06 lg/mL). BLPAR strains
showed high levels of resistance to PIPC, with MIC90
values of C256 lg/mL, whereas TAZ/PIPC showed strong
activities, with MIC90s of B0.06 lg/mL. Among the cef-
ems, CDTR and CTRX showed the most potent activities,
with MIC90s of 0.25 lg/mL. Of the ﬁve carbapenem
agents, MEPM showed the most potent acvitity against all
types of H. inﬂuenzae strains. Among the macrolides, AZM
showed the most potent acvitity, with an MIC90 of 2 lg/
mL.
Moraxella catarrhalis
The susceptibilities of 106 M. catarrhalis strains are shown
in Table 5. For the penicillins, b-lactamase inhibitors
restored the activities of penicillins; e.g., SBT decreased
the MIC90 of ABPC from 8 to 0.25 lg/mL and TAZ
decreased the MIC90 of PIPC from 4 to B0.06 lg/mL.
Carbapenems showed strong activities, with MIC90s of
B0.25 lg/mL; in particular, MEPM and DRPM showed the
most potent activities, with MICs for all isolates of
B0.06 lg/mL. Fluoroquinolones also showed strong
activities, with MIC90s of B0.06 lg/mL. Several cephems
(CFDN, CFPN, CDTR, CTRX, CAZ, and CMZ), two
aminoglycosides (GM and ABK), three macrolides (EM,
CAM, and AZM), and the ketolide (TEL) also showed
potent activities, with MIC90s of 0.125–1.0 lg/mL.
Klebsiella pneumoniae
The susceptibilities of 126 K. pneumoniae strains are shown
in Table 6. Among 34 antimicrobial agents we tested,
MEPM and DRPM showed the strongest activities, with
MIC90s of B0.06 lg/mL. Of the cephems and the mono-
bactam, CFDN, CAZ, CTRX CFPM, CZOP, and AZT
showed strong activities, with MIC90s of 0.125–0.25 lg/
mL. All ﬂuoroquinolones we tested and two aminoglyco-
sides (GM and ABK) also showed potent activities, with
MIC90s of 0.25–0.5 lg/mL. b-Lactamase inhibitors appar-
ently restored the activities of penicillins; e.g., SBT
decreased the MIC90 of ABPC from C256 to 8 lg/mL and
TAZ decreased the MIC90 of PIPC from 32 to 4 lg/mL.
Among the 126 strains of K. pneumoniae, 4 strains (3.2%)
were found to be ESBL producers.
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Table 3 Antibacterial susceptibility of Streptococcus pneumoniae
Antibacterial
agent
All strains (n = 210) PSSP (PCG B 0.06) (n = 110) PISP (PCG B 0.125, C1) (n = 75) PRSP (PCG C 2) (n = 25)
MIC (lg/mL) MIC (lg/mL) MIC (lg/mL) MIC (lg/mL)
50% 90% Range 50% 90% Range 50% 90% Range 50% 90% Range
PCG B0.06 2 B0.06 to 4 B0.06 B0.06 B0.06 0.5 1 0.125 to 1 2 2 2 to 4
ABPC 0.125 2 B0.06 to 8 B0.06 B0.06 B0.06 to 0.25 0.5 2 B0.06 to 4 4 4 2 to 8
SBT/ABPC 0.125 2 B0.06 to 8 B0.06 B0.06 B0.06 to 0.25 0.5 2 B0.06 to 4 4 4 2 to 8
CVA/AMPC B0.06 1 B0.06 to 4 B0.06 B0.06 B0.06 to 0.125 0.25 0.5 B0.06 to 1 1 2 0.5 to 4
PIPC B0.06 2 B0.06 to 4 B0.06 B0.06 B0.06 to 0.5 0.5 2 B0.06 to 2 2 2 1 to 4
TAZ/PIPC B0.06 2 B0.06 to 4 B0.06 B0.06 B0.06 to 0.5 0.5 2 B0.06 to 2 2 2 0.5 to 4
CCL 2 64 B0.06 to 128 0.5 1 B0.06 to 8 16 64 0.5 to 64 64 128 32 to 128
CFDN 0.25 4 B0.06 to 16 0.125 0.25 B0.06 to 2 2 4 0.125 to 8 8 8 4 to 16
CFPN 0.25 1 B0.06 to 16 0.125 0.25 B0.06 to 8 0.5 1 B0.06 to 4 1 4 0.5 to 16
CDTR 0.125 0.5 B0.06 to 8 B0.06 0.125 B0.06 to 4 0.25 0.5 B0.06 to 2 0.5 2 0.5 to 8
CEZ 0.25 4 B0.06 to 8 0.125 0.25 B0.06 to 0.5 2 4 0.25 to 8 4 4 2 to 8
CTM 0.5 4 B0.06 to 8 0.25 0.5 B0.06 to 2 2 4 0.25 to 8 4 8 2 to 8
CAZ 4 8 B0.06 to 64 2 4 B0.06 to 64 8 8 0.25 to 32 8 32 8 to 64
CTRX 0.25 1 B0.06 to 8 0.125 0.25 B0.06 to 8 0.5 1 B0.06 to 4 1 2 0.5 to 8
CFPM 0.5 2 B0.06 to 8 0.25 0.5 B0.06 to 4 1 2 0.125 to 4 2 4 1 to 8
CZOP 0.25 2 B0.06 to 8 0.125 0.5 B0.06 to 8 0.5 1 B0.06 to 4 2 4 0.5 to 8
CMZ 0.5 8 B0.06 to 32 0.25 0.5 B0.06 to 1 4 8 0.25 to 16 16 16 8 to 32
IPM B0.06 0.5 B0.06 to 2 B0.06 B0.06 B0.06 to 0.125 0.125 0.5 B0.06 to 2 0.5 1 0.125 to 2
PAPM B0.06 0.25 B0.06 to 0.5 B0.06 B0.06 B0.06 B0.06 0.25 B0.06 to 0.5 0.25 0.5 B0.06 to 0.5
MEPM B0.06 0.5 B0.06 to 0.5 B0.06 B0.06 B0.06 to 0.125 0.125 0.25 B0.06 to 0.5 0.5 0.5 0.25 to 0.5
BIPM B0.06 0.25 B0.06 to 0.5 B0.06 B0.06 B0.06 0.125 0.25 B0.06 to 0.5 0.25 0.5 0.125 to 0.5
DRPM B0.06 0.25 B0.06 to 0.5 B0.06 B0.06 B0.06 0.125 0.25 B0.06 to 0.5 0.25 0.5 0.125 to 0.5
FRPM B0.06 0.25 B0.06 to 0.5 B0.06 B0.06 B0.06 to 0.125 0.125 0.25 B0.06 to 0.25 0.25 0.5 0.125 to 0.5
GM 8 8 0.5 to 16 4 8 0.5 to 16 8 8 2 to 16 8 8 4 to 16
AMK 32 64 4 to 128 32 64 4 to 128 64 64 16 to 128 64 64 32 to 128
ABK 16 32 2 to 64 16 32 2 to 64 16 32 8 to 64 16 32 16 to 32
CPFX 1 2 0.125 to 32 1 2 0.125 to 16 1 2 0.25 to 32 1 4 0.5 to 32
LVFX 1 2 B0.06 to 16 1 2 B0.06 to 4 1 2 0.5 to 16 1 2 0.5 to 16
TFLX 0.125 0.25 B0.06 to C32 0.125 0.25 B0.06 to 0.5 0.125 0.25 B0.06 to C32 0.125 0.25 0.125 to C32
GFLX 0.25 0.5 B0.06 to 8 0.25 0.5 B0.06 to 2 0.25 0.5 0.125 to 4 0.25 0.5 0.25 to 8
PZFX 2 4 B0.06 to 32 2 4 B0.06 to 8 2 4 1 to 32 2 4 2 to 32
MFLX 0.25 0.25 B0.06 to 4 0.25 0.25 B0.06 to 0.5 0.125 0.25 B0.06 to 4 0.25 0.25 0.125 to 4
MINO 4 8 B0.06 to 32 4 8 B0.06 to 32 8 8 B0.06 to 32 8 16 0.125 to 16
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Pseudomonas aeruginosa
A total of 162 P. aeruginosa strains were tested for anti-
microbial susceptibility (Table 7). Among the b-lactams,
three carbapenems (MEPM, BIPM, and DRPM) showed
potent activities, with MIC50s of 0.25–0.5 lg/mL; how-
ever, these agents showed relatively higher MIC90 levels,
of 8.0–16 lg/mL. Among the ﬂuoroquinolones, CPFX
showed the most potent activity, with MIC50s and MIC90s
of 0.25 and 4.0 lg/mL, respectively. Other ﬂuoroquino-
lones also showed strong activities, with MIC50s of
0.25–2.0 lg/mL, whereas the MIC90 levels (8.0 to C32 lg/
mL) suggested partial resistance. Both PIPC and TAZ/
PIPC showed potent activities, with MIC50s of 4 lg/mL;
higher MIC90 levels (128 and 64 lg/mL) of these agents
suggested resistance. The MIC50s of the three aminogly-
cosides (GM, AMK, and ABK), three cephems (CAZ,
CFPM and CZOP), and the monobactam (AZT) were
within the range of 1.0–4.0 lg/mL. Only one strain was
identiﬁed as multidrug-resistant P. aeruginosa (MDRP)
from its proﬁle of resistance to IPM, AMK, and CPFX.
Among the 162 P. aeruginosa strains, we found 4 (2.5%)
MBL-producing strains and 3 multidrug-resistant strains
(1.9%), and these 3 multidrug-resistant strains were found
to be MBL-producers.
Discussion
The Japanese Society of Chemotherapy (JSC) established a
nationwide surveillance network in 2006 to establish a
resource for information about the antimicrobial suscepti-
bility of bacterial pathogens in Japan. Our research focuses
on seven major bacterial respiratory pathogens – S. aureus,
S. pneumoniae, S. pyogenes, H. inﬂuenzae, M. catarrhalis,
K. pneumoniae, and P. aeruginosa. It is desirable that
analysis of antimicrobial susceptibility is done with the use
of bacterial strains that actually cause the infections. To
analyze the actual pathogens causing infections, we col-
lected clinical isolates only from well-diagnosed adult
patients with respiratory tract infections (RTIs).
Our surveillance was conducted for three consecutive
years from 2006. The total number of strains collected for
the surveillances conducted in 2006, 2007, and 2008 were
887, 1108, and 987, respectively. The species tested at
surveillance in each of these years were as follows:
S. aureus (205, 226, and 189), S. pneumoniae (200, 257,
and 211), H. inﬂuenzae (165, 206, and 187), P. aeruginosa
(143, 171, and 162), M. catarrhalis (91, 120, and 106),
K. pneumoniae (74, 122, and 126), and S. pyogenes (9, 6,
and 6). The numbers of each species in each year of sur-
veillance may generally reﬂect the trend of pathogens of
respiratory infections in Japan, but we think we shouldT
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Table 4 Antibacterial susceptibility of Haemophilus inﬂuenzae
Antibacterial agent All strains (n = 187) BLNAS [ABPC B 1, b-
lactamase (-)] (n = 101)
BLNAI [ABPC = 2, b-
lactamase (-)] (n = 26)
BLNAR [ABPC C 4, b-
lactamase (-)] (n = 50)
BLPAR [ABPC C 4 lg/mL,
b-lactamase (?)] (n = 10)
MIC (lg/mL) MIC (lg/mL) MIC (lg/mL) MIC (lg/mL) MIC (lg/mL)
50% 90% Range 50% 90% Range 50% 90% Range 50% 90% Range 50% 90% Range
PCG 2 8 B0.06 to C256 0.5 2 B0.06 to 8 2 8 1 to 8 8 8 2 to 16 64 C256 4 to C256
ABPC 1 8 0.125 to C256 0.25 1 0.125 to 1 2 2 2 4 8 4 to 16 128 C256 4 to C256
SBT/ABPC 1 8 0.125 to 16 0.25 1 0.125 to 1 2 4 1 to 4 4 8 4 to 16 2 8 0.5 to 16
CVA/AMPC 2 16 0.125 to 32 0.5 2 0.125 to 8 4 8 0.5 to 16 8 16 4 to 32 1 16 0.5 to 16
PIPC B0.06 0.125 B0.06 to C256 B0.06 0.125 B0.06 to 0.5 B0.06 0.25 B0.06 to 0.25 B0.06 0.125 B0.06 to 0.25 16 C256 4 to C256
TAZ/PIPC B0.06 0.125 B0.06 to 0.5 B0.06 B0.06 B0.06 to 0.5 B0.06 0.125 B0.06 to 0.25 B0.06 0.125 B0.06 to 0.25 B0.06 B0.06 B0.06 to 0.125
CCL 8 64 0.125 to C256 4 16 0.125 to 64 8 64 2 to 128 64 128 4 to C256 8 128 1 to 128
CFDN 1 8 B0.06 to 16 0.25 4 B0.06 to 8 1 8 B0.06 to 8 4 8 0.25 to 16 0.25 4 0.125 to 8
CFPN 0.25 2 B0.06 to 8 B0.06 0.5 B0.06 to 2 1 2 B0.06 to 4 2 4 B0.06 to 8 B0.06 1 B0.06 to 2
CDTR B0.06 0.25 B0.06 to 0.5 B0.06 B0.06 B0.06 to 0.5 0.125 0.25 B0.06 to 0.5 0.25 0.25 B0.06 to 0.5 B0.06 0.125 B0.06 to 0.25
CEZ 8 C256 0.25 to C256 8 32 0.25 to C256 8 128 1 to C256 64 C256 1 to C256 4 C256 1 to C256
CTM 8 64 0.125 to C256 2 16 0.125 to 64 8 64 2 to 64 64 128 2 to C256 4 64 0.5 to 128
CAZ 0.25 0.5 B0.06 to 2 0.125 0.5 B0.06 to 2 0.25 1 B0.06 to 1 0.5 1 0.125 to 2 B0.06 0.25 B0.06 to 0.5
CTRX B0.06 0.25 B0.06 to 1 B0.06 0.125 B0.06 to 0.25 0.25 0.25 B0.06 to 0.25 0.25 0.25 B0.06 to 1 B0.06 0.125 B0.06 to 0.25
CFPM 0.5 4 B0.06 to 8 0.125 1 B0.06 to 2 2 2 0.25 to 4 2 4 0.5 to 8 0.125 1 B0.06 to 4
CZOP 4 8 B0.06 to C256 0.125 4 B0.06 to 16 8 8 0.5 to 8 8 16 2 to C256 0.25 4 B0.06 to 16
CMZ 4 32 B0.06 to 128 2 8 B0.06 to 64 8 16 2 to 32 16 32 4 to 128 4 16 0.25 to 32
AZT 0.25 2 B0.06 to 8 B0.06 0.5 B0.06 to 4 0.5 1 B0.06 to 2 1 4 B0.06 to 8 B0.06 0.5 B0.06 to 2
IPM 1 4 B0.06 to 8 0.5 2 B0.06 to 8 1 2 0.125 to 4 2 8 0.25 to 8 0.5 4 B0.06 to 8
PAPM 0.5 4 B0.06 to 8 0.5 2 B0.06 to 4 1 2 0.125 to 4 2 4 0.25 to 8 0.5 4 B0.06 to 8
MEPM B0.06 0.5 B0.06 to 1 B0.06 0.125 B0.06 to 0.5 0.125 0.25 B0.06 to 0.5 0.25 0.5 B0.06 to 1 B0.06 0.125 B0.06 to 0.25
BIPM 1 8 B0.06 to 16 0.5 4 B0.06 to 8 2 4 B0.06 to 8 4 8 0.25 to 16 0.5 8 B0.06 to 8
DRPM 0.25 1 B0.06 to 4 0.125 0.25 B0.06 to 1 0.25 0.5 B0.06 to 2 1 2 B0.06 to 4 0.125 2 B0.06 to 2
FRPM 1 4 B0.06 to 8 0.5 2 0.125 to 4 1 4 0.25 to 4 2 4 0.5 to 8 0.5 4 B0.06 to 4
GM 2 2 0.25 to 4 2 2 0.25 to 4 1 2 0.25 to 2 2 2 0.5 to 2 2 2 0.5 to 4
AMK 4 8 2 to 16 4 8 2 to 16 4 8 2 to 8 4 8 2 to 8 4 8 2 to 16
ABK 4 4 1 to 8 4 8 1 to 8 4 4 2 to 4 4 4 2 to 8 4 8 2 to 8
CPFX B0.06 B0.06 B0.06 to 1 B0.06 B0.06 B0.06 to 0.125 B0.06 B0.06 B0.06 to 0.125 B0.06 B0.06 B0.06 to 1 B0.06 B0.06 B0.06
LVFX B0.06 B0.06 B0.06 to 4 B0.06 B0.06 B0.06 to 0.125 B0.06 B0.06 B0.06 to 0.125 B0.06 B0.06 B0.06 to 4 B0.06 B0.06 B0.06
TFLX B0.06 B0.06 B0.06 to 0.25 B0.06 B0.06 B0.06 B0.06 B0.06 B0.06 to 0.125 B0.06 B0.06 B0.06 to 0.25 B0.06 B0.06 B0.06
GFLX B0.06 B0.06 B0.06 to 1 B0.06 B0.06 B0.06 to 0.25 B0.06 B0.06 B0.06 to 0.125 B0.06 B0.06 B0.06 to 1 B0.06 B0.06 B0.06 to 0.125
PZFX B0.06 B0.06 B0.06 to 2 B0.06 B0.06 B0.06 to 0.25 B0.06 0.125 B0.06 to 0.25 B0.06 B0.06 B0.06 to 2 B0.06 B0.06 B0.06 to 0.125
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increase the scope of the survey by reﬂecting results with a
greater number of pathogens.
With regard to S. aureus, in the present survey, 42 of 76
strains (55.2%) of MSSA were thought to be penicillinase-
producing strains because of their resistance to ABPC and
Table 5 Antibacterial susceptibility of Moraxella catarrhalis
Antibacterial agent MIC (lg/mL) (n = 106)
50% 90% Range
PCG 8 16 B0.06 to 64
ABPC 2 8 B0.06 to 64
SBT/ABPC 0.125 0.25 B0.06 to 0.5
CVA/AMPC 0.125 0.25 B0.06 to 0.5
PIPC 0.5 4 B0.06 to 64
TAZ/PIPC B0.06 B0.06 B0.06 to 0.5
CCL 0.5 4 0.125 to 8
CFDN 0.125 0.25 B0.06 to 0.5
CFPN 0.5 0.5 B0.06 to 1
CDTR 0.25 1 B0.06 to 2
CEZ 4 8 0.25 to 16
CTM 1 2 0.25 to 4
CAZ 0.125 0.25 B0.06 to 4
CTRX 0.5 2 B0.06 to 2
CFPM 1 4 0.125 to 8
CZOP 2 4 0.125 to 8
CMZ 0.5 1 B0.06 to 2
AZT 2 4 0.25 to C256
IPM 0.125 0.25 B0.06 to 1
PAPM B0.06 0.125 B0.06 to 0.25
MEPM B0.06 B0.06 B0.06
BIPM B0.06 0.125 B0.06 to 0.125
DRPM B0.06 B0.06 B0.06
FRPM 0.25 0.5 B0.06 to 1
GM 0.125 0.25 B0.06 to 0.25
AMK 0.5 2 0.25 to 2
ABK 0.25 0.25 0.125 to 0.5
CPFX B0.06 B0.06 B0.06 to 0.5
LVFX B0.06 B0.06 B0.06 to 2
TFLX B0.06 B0.06 B0.06 to 2
GFLX B0.06 B0.06 B0.06 to 0.5
PZFX B0.06 B0.06 B0.06 to 2
MFLX B0.06 0.125 B0.06 to 0.5
MINO 0.125 0.125 B0.06 to 0.5
EM 0.125 0.25 B0.06 to 0.5
CAM 0.125 0.25 B0.06 to 0.5
AZM B0.06 B0.06 B0.06
TEL 0.125 0.125 B0.06 to 0.25
CLDM 4 4 0.25 to 8
Susceptibilities of the 106 strains of M. catarrhalis to 39 antimicro-
bial agents were studied
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susceptibility to SBT/ABPC and CCL, and 11 of 76 strains
(14.5%) of MSSA may be emr-harboring strains because of
their resistance to the macrolides, EM, CAM, and AZM,
and susceptibility to TEL (ketolide lacking emr resistance
mechanism) [4]. The difference between MSSA resistance
to GM (10.5%) and that to AMK (0%) implied the coex-
istence of aac(60)/aph(200)-harboring GM-resistant strains
with aad(40, 400)-harboring AMK-resistant strains [5].
We found the incidence of MRSA to be as high as
59.8%, which is similar to the data reported by Mochizuki
et al. [6] in a study analyzed with the microbiology labo-
ratory database software WHONET 5. These MRSA strains
are susceptible to ABK, VCM, TEIC, and LZD, except that
a few strains are somewhat less susceptible (MIC: 8.0 lg/
mL) to ABK; these strains may possess both aph(30)-III
and aac(60)/aph(200) genes, as reported recently [5].
Although the emergence of MRSA that is resistant to
VCM, TEIC, or LZD has already been reported in Japan,
such a resistant strain was not detected in the present
survey.
Regarding S. pneumoniae, the proportion of PSSP/PISP/
PRSP was found to be 53:35:12. The proportions of each
group of strains in the ﬁrst and second years of surveillance
were at similar levels (61:35:4 and 65:30:5, respectively),
but the results of the third year of surveillance suggest an
increase in resistant strains of S. pneumoniae. Among
PSSP, more than 55% are thought to be emr-harboring
strains because of their resistance to macrolides (EM,
CAM, and AZM) and CLDM and susceptibility to the
ketolide TEL. As for PISP, their incidence (35%) in this
survey of adult RTIs was much lower than that (50.8%)
reported in pediatric infections [7–9]. The incidence of
PRSP (12%) in our present survey was relatively low as
Table 6 Antibacterial susceptibility of Klebsiella pneumoniae
Antibacterial agent MIC (lg/mL) (n = 126)
50% 90% Range
ABPC 64 C256 0.5 to C256
SBT/ABPC 4 8 0.5 to C256
CVA/AMPC 2 8 0.5 to C128
PIPC 4 32 0.125 to C256
TAZ/PIPC 2 4 B0.06 to C256
CCL 0.25 1 0.25 to C256
CFDN 0.125 0.25 B0.06 to C128
CFPN 0.25 1 B0.06 to 128
CDTR 0.125 0.5 B0.06 to C128
CEZ 1 4 0.5 to C256
CTM 0.125 1 B0.06 to C256
CAZ 0.125 0.25 B0.06 to C128
CTRX B0.06 0.125 B0.06 to C256
CFPM B0.06 0.25 B0.06 to 128
CZOP B0.06 0.125 B0.06 to C256
CMZ 0.5 2 0.25 to 64
AZT B0.06 0.125 B0.06 to C256
IPM 0.25 1 B0.06 to 2
PAPM 0.25 0.5 B0.06 to 2
MEPM B0.06 B0.06 B0.06 to 0.25
BIPM 0.125 0.25 B0.06 to 1
DRPM B0.06 B0.06 B0.06 to 0.25
FRPM 0.25 1 0.125 to 8
GM 0.25 0.5 0.125 to 64
AMK 1 2 0.5 to 16
ABK 0.5 0.5 0.25 to 8
CPFX B0.06 0.25 B0.06 to 32
LVFX B0.06 0.5 B0.06 to 32
TFLX B0.06 0.25 B0.06 to C32
GFLX B0.06 0.5 B0.06 to 32
PZFX B0.06 0.25 B0.06 to 16
MFLX 0.125 0.5 B0.06 to 32
MINO 2 4 0.25 to 64
AZM 8 16 0.5 to C128
Susceptibilities of the 126 strains of K. pneumoniae to 34 antimi-
crobial agents were studied
Table 7 Antibacterial susceptibility of Pseudomonas aeruginosa
Antibacterial agent MIC (lg/mL) (n = 162)
50% 90% Range
PIPC 4 128 0.25 to C256
TAZ/PIPC 4 64 0.125 to C256
CAZ 2 16 0.125 to C128
CTRX 64 C256 0.25 to C256
CFPM 2 16 0.125 to C256
CZOP 1 8 0.125 to C256
IPM 2 16 B0.06 to C128
PAPM 8 32 B0.06 to C256
MEPM 0.5 8 B0.06 to C256
BIPM 0.5 16 B0.06 to C256
DRPM 0.25 8 B0.06 to C128
AZT 4 16 B0.06 to C256
GM 1 4 B0.06 to C256
AMK 2 8 0.125 to C256
ABK 1 4 B0.06 to C256
CPFX 0.25 4 B0.06 to C256
LVFX 1 16 B0.06 to C256
TFLX 0.25 C32 B0.06 to C32
GFLX 1 16 B0.06 to C256
PZFX 0.5 8 B0.06 to C256
MFLX 2 16 B0.06 to C256
MINO 16 128 B0.06 to C256
Susceptibilities of the 162 strains of P. aeruginosa to 22 antimicrobial
agents were analyzed
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compared with the data (16.9–49.0%) reported in pediatric
infections [7–9]. This difference is thought to be attribut-
able to the excess use of oral penicillins and cephems for
the treatment of children, because the use of ﬂuoroquino-
lones (except for norﬂoxacin) is contraindicated in children
in Japan. Although TFLX has been permitted for the
treatment for children in 2010, the present research was
conducted in 2008. The pattern of susceptibility of PRSP
somewhat resembled that of PISP; however, PRSP were
substantially susceptible (MIC90s: B0.5 lg/mL) only to
carbapenems, except for IPM, and they were not suscep-
tible to TFLX, GFLX, MFLX, TEL, and VCM.
The FDA has raised the concentration at which S.
pneumoniae is considered to be susceptible to penicillin for
the treatment of pneumonia, although the susceptibility
breakpoint for meningitis remains unchanged (0.06 lg/
mL). With the new criteria for breakpoint MICs, only one
of the 211 S. pneumoniae strains (0.5%) in the present
survey was found to be intermediate and the other 210
strains (99.5%) were classiﬁed as susceptible. These results
suggest that penicillin is still effective against community-
acquired pneumonia caused by S. pneumoniae.
Concerning H. inﬂuenzae, half of the strains in the
present survey showed decreased susceptibility to ABPC
without production of b-lactamase; BLNAI (13.9%) and
BLNAR (26.7%). The incidence of BLNAI in adults is
thought to be somewhat lower (30.4%) than that in children
[10]. All six ﬂuoroquinolones demonstrated extremely
strong activity (MIC90: B0.06 lg/mL) against H. inﬂuen-
zae strains, regardless of their ABPC susceptibility. Among
the rest of the agents, PIPC, TAZ/PIPC, CDTR, CTRX,
and MEPM showed strong activities (MIC90s of
0.125–0.5 lg/mL) against BLNAS, BLNAI, and BLNAR
strains. TAZ markedly restored the activity of PIPC against
BLPAR (MIC90 decreased from C256 to B0.06 lg/mL).
The susceptibilities of M. catarrhalis in the present
survey showed that b-lactamase inhibitors restored the
activities of penicillins against these strains: SBT
decreased the MIC90 of ABPC from 8 to 0.25 lg/mL. The
data suggest that most of the strains were resistant to
penicillins because of b-lactamase production. For the
treatment of M. catarrhalis infections, carbapenems,
macrolides, and ﬂuoroquinolones may be recommended
because these drugs showed strong activities, with MIC90s
of B0.06–0.25 lg/mL.
The prevalence of extended-spectrum b-lactamase
(ESBL) strains has become a concern in recent years. Yagi
et al. conducted a survey of ESBLs among 9,794 K. pneu-
moniae clinical isolates in Japan during the period January
1997 to January 1998 and they reported that 34 isolates
(0.3%) had been found to produce ESBLs [11]. However,
an increase in the number of ESBL-producing strains has
been suggested; Yamaguchi et al. [12] reported the results
of a nationwide surveillance of antibacterial activity of
clinical isolates in 2006, and 3.3% (3 of 91) K. pneumoniae
strains were found to be ESBL-producing strains. In our
study, 4 of 126 K. pneumoniae strains (3.2%) were found to
be ESBL-producing strains, and these results were con-
sistent with the previous report.
In the present survey, 4 (2.5%) metallo-b-lactamase
(MBL)-producing strains and 3 (1.9%) multidrug-resistant
strains were found in 162 P. aeruginosa isolates. Yamag-
uchi et al. compared the frequencies of multidrug-resistant
strains of P. aeruginosa between isolates from urinary tract
infections and those from RTIs. They reported that 5.6 and
1.8% of multidrug-resistant strains were found from the
urinary isolates and the respiratory isolates, respectively.
Therefore, a low incidence of multidrug-resistant P. aeru-
ginosa may be limited to respiratory infections [13].
The present study has revealed, in comparison to that of
2007, that the incidence of S. pneumoniae isolation was
higher in 2008, while the frequencies of other bacterial
species were comparable to those in 2007. The total fre-
quency of S. pneumoniae isolation, including PISP and
PRSP, increased from 35.5% in 2007 to 47.3% in 2008; the
difference was statistically signiﬁcant, at P\ 0.001.
Because the frequencies of PISP in 2007 and 2008 showed
no signiﬁcant difference, the contribution of the PRSP
isolation frequency must have been markedly high in 2008.
In fact, the frequency of PRSP isolation in 2007 was 5.1%
and that in 2008 was 11.8%; this is a statistically signiﬁcant
difference, at P\ 0.001. Thus, careful watching of the
trend of PRSP may be needed [14].
We think our surveillance data will be a useful reference
for the treatment of respiratory infections in our country.
There is substantial evidence that the overuse of antibiotics
is a major cause of the emergence of resistance in respi-
ratory pathogens. To prevent the further spread of antimi-
crobial resistance in respiratory pathogens, proper
antibiotic use is needed. We should also continue the sur-
veillance to determine the actual situation of the resistance
shown by bacterial respiratory pathogens to antimicrobial
agents.
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